SOHM Inc. Awarded European Patent for Innovative ABBIE Genome Editing Technology

Rhea-AI Summary

SOHM Inc. (OTC:SHMN) has secured a European patent for its innovative ABBIE genome editing technology. The patent (No. 3,277,805) specifically covers CAS 9 retroviral integrase and CAS 9 recombinase systems for targeted DNA sequence incorporation into cell or organism genomes. This achievement follows a recent patent grant in South Korea, with the European patent set to be published in the Patent Office Bulletin on May 7, 2025.

According to COO David Aguilar, this technology has significant potential applications in targeted gene therapies, cell therapy development, genetic disorder treatments, and agricultural improvements. The patent grant strengthens SOHM's position in the biotechnology sector and demonstrates its commitment to innovative R&D.

Positive

• European patent granted for ABBIE genome editing technology
• Technology has potential applications in gene therapies, cell therapies, genetic disorders, and agriculture
• Recent patent also granted in South Korea, expanding international IP protection

Negative

• None.

CHINO HILLS, CA / ACCESS Newswire / May 1, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces today the granting of a European patent for its groundbreaking technology for genome editing, specifically focusing on its ABBIE editing system. The European Patent Application No. 16715977.1, titled CAS 9 RETROVIRAL INTEGRASE AND CAS 9 RECOMBINASE SYSTEMS FOR TARGETED INCORPORATION OF A DNA SEQUENCE INTO A GENOME OF A CELL OR ORGANISM, has been officially granted as Patent No. 3,277,805.

This significant milestone follows the recent granting of a patent in South Korea. The grant of this patent will be published in the European Patent Office Patent Bulletin No. 25/19 on May 7, 2025.

David Aguilar, COO of SOHM Inc., expressed his enthusiasm about the patent grant, stating, "We are incredibly proud to receive this patent, which not only recognizes our innovative work in genome editing but also reinforces our commitment to advancing biotechnology for the betterment of society. This technology has the potential to enhance targeted gene therapies, revolutionizing approaches to develop cell therapies, treat genetic disorders and to improve agricultural practices."

This patent addition to SOHM Inc.'s portfolio underscores the company's dedication to pioneering solutions in the biotechnology sector, further solidifying its position as a leader in innovative research and development.

For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.

About SOHM, Inc.:

SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.

For further information regarding this announcement or to explore potential collaborations, please contact:

SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700

Safe Harbor Statement:

This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.

SOURCE: SOHM, Inc

View the original press release on ACCESS Newswire

FAQ

What is the European patent number granted to SOHM Inc (SHMN) for its ABBIE technology?

SOHM Inc. was granted European Patent No. 3,277,805 for its ABBIE genome editing technology.

When will SOHM's (SHMN) European patent be published in the Patent Office Bulletin?

The patent will be published in the European Patent Office Patent Bulletin No. 25/19 on May 7, 2025.

What are the potential applications of SOHM's (SHMN) ABBIE genome editing technology?

The technology has potential applications in targeted gene therapies, cell therapy development, genetic disorder treatments, and agricultural improvements.

In which countries does SOHM (SHMN) now hold patents for its ABBIE technology?

SOHM holds patents for its ABBIE technology in Europe and South Korea.